Holen Sie sich die Stockscreener-App
84.58
0.29%
-0.25
Handel nachbörslich:
84.58
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt EW?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$84.83
Offen:
$84.28
24-Stunden-Volumen:
3.74M
Relative Volume:
0.95
Marktkapitalisierung:
$49.08B
Einnahmen:
$5.88B
Nettoeinkommen (Verlust:
$1.34B
KGV:
36.01
EPS:
2.3489
Netto-Cashflow:
$799.60M
1W Leistung:
-0.79%
1M Leistung:
+0.31%
6M Leistung:
+10.72%
1J Leistung:
+14.07%
1-Tages-Spanne:
$84.25
$85.53
1-Wochen-Bereich:
$83.66
$86.60
52-Wochen-Spanne:
$65.94
$87.89
Edwards Lifesciences Corp Stock (EW) Company Profile
Firmenname
Edwards Lifesciences Corp
Sektor
Branche
Telefon
(949) 250-2500
Adresse
ONE EDWARDS WAY, IRVINE, CA
Vergleichen Sie EW mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EW
Edwards Lifesciences Corp
|
84.58 | 49.23B | 5.88B | 1.34B | 799.60M | 2.3489 |
|
ABT
Abbott Laboratories
|
126.18 | 220.91B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
98.38 | 146.24B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
367.21 | 140.64B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
98.69 | 127.91B | 34.76B | 4.79B | 5.21B | 3.7017 |
Edwards Lifesciences Corp Stock (EW) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-18 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2025-11-03 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2025-10-29 | Hochstufung | Jefferies | Hold → Buy |
| 2025-10-29 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2025-10-08 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2025-10-07 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2025-07-29 | Hochstufung | BTIG Research | Neutral → Buy |
| 2025-04-24 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2025-01-30 | Hochstufung | Stifel | Hold → Buy |
| 2025-01-16 | Herabstufung | Wolfe Research | Peer Perform → Underperform |
| 2024-12-16 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-10-11 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2024-09-18 | Herabstufung | Jefferies | Buy → Hold |
| 2024-07-31 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2024-07-29 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2024-07-25 | Herabstufung | BofA Securities | Buy → Neutral |
| 2024-07-25 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-07-25 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-07-25 | Herabstufung | TD Cowen | Buy → Hold |
| 2024-07-25 | Herabstufung | Truist | Buy → Hold |
| 2024-05-30 | Eingeleitet | Goldman | Buy |
| 2024-05-22 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-05-14 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2024-03-07 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-02-02 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-01-04 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2023-12-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-11-28 | Herabstufung | Wolfe Research | Peer Perform → Underperform |
| 2023-09-26 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2023-07-19 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Overweight |
| 2023-03-29 | Eingeleitet | UBS | Neutral |
| 2023-03-08 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-02-06 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2023-01-31 | Herabstufung | Bernstein | Outperform → Underperform |
| 2023-01-30 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-12-06 | Herabstufung | Stifel | Buy → Hold |
| 2022-10-28 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2022-10-26 | Eingeleitet | Mizuho | Buy |
| 2022-10-18 | Eingeleitet | Barclays | Overweight |
| 2022-10-12 | Eingeleitet | Jefferies | Buy |
| 2022-07-29 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2022-04-13 | Eingeleitet | Truist | Buy |
| 2022-04-06 | Eingeleitet | Wolfe Research | Outperform |
| 2022-03-16 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2022-03-02 | Fortgesetzt | BofA Securities | Neutral |
| 2022-02-02 | Hochstufung | UBS | Neutral → Buy |
| 2022-01-27 | Bestätigt | Citigroup | Buy |
| 2022-01-27 | Bestätigt | Evercore ISI | Outperform |
| 2022-01-27 | Bestätigt | Raymond James | Outperform |
| 2022-01-27 | Bestätigt | Stifel | Buy |
| 2022-01-27 | Bestätigt | UBS | Neutral |
| 2021-12-17 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-12-15 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-12-10 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-12-06 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2021-07-30 | Bestätigt | Canaccord Genuity | Buy |
| 2021-07-30 | Bestätigt | Deutsche Bank | Hold |
| 2021-07-30 | Bestätigt | Jefferies | Buy |
| 2021-07-30 | Bestätigt | Morgan Stanley | Overweight |
| 2021-07-30 | Bestätigt | Oppenheimer | Outperform |
| 2021-07-30 | Bestätigt | Stifel | Buy |
| 2021-07-30 | Bestätigt | UBS | Neutral |
| 2021-07-30 | Bestätigt | Wells Fargo | Equal Weight |
| 2021-05-25 | Eingeleitet | Barclays | Overweight |
| 2021-04-15 | Eingeleitet | Atlantic Equities | Neutral |
| 2021-04-05 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2020-12-16 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-12-11 | Bestätigt | Canaccord Genuity | Buy |
| 2020-09-11 | Eingeleitet | Wolfe Research | Underperform |
| 2020-04-28 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2020-02-13 | Eingeleitet | Goldman | Neutral |
| 2020-02-06 | Fortgesetzt | BTIG Research | Neutral |
| 2020-01-10 | Eingeleitet | Oppenheimer | Outperform |
| 2020-01-02 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-10-24 | Bestätigt | Canaccord Genuity | Buy |
| 2019-09-23 | Eingeleitet | Piper Jaffray | Overweight |
| 2019-07-24 | Bestätigt | BofA/Merrill | Buy |
| 2019-03-18 | Bestätigt | Canaccord Genuity | Buy |
| 2019-01-18 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-01-03 | Eingeleitet | Deutsche Bank | Hold |
| 2018-11-28 | Eingeleitet | UBS | Neutral |
| 2018-10-16 | Eingeleitet | Barclays | Underweight |
| 2018-10-02 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2018-10-02 | Herabstufung | Guggenheim | Buy → Neutral |
Alle ansehen
Edwards Lifesciences Corp Aktie (EW) Neueste Nachrichten
Is Edwards Lifesciences Corporation stock gaining market shareWeekly Gains Summary & Long-Term Safe Investment Ideas - ulpravda.ru
Robeco Institutional Asset Management B.V. Decreases Stock Position in Edwards Lifesciences Corporation $EW - MarketBeat
Stifel Nicolaus Increases Edwards Lifesciences (NYSE:EW) Price Target to $105.00 - MarketBeat
Stifel Maintains Buy on Edwards Lifesciences (EW) and Raises Pri - GuruFocus
Stifel raises Edwards Lifesciences stock price target to $105 on growth outlook - Investing.com
Donald Bobo Jr Sells 11,340 Shares of Edwards Lifesciences (NYSE:EW) Stock - MarketBeat
Edwards Lifesciences completes key study on SAPIEN XT THV - MSN
Edwards Lifesciences (NYSE:EW) Will Want To Turn Around Its Return Trends - simplywall.st
Econ Financial Services Corp Acquires 15,836 Shares of Edwards Lifesciences Corporation $EW - MarketBeat
Ninety One UK Ltd Buys 969,030 Shares of Edwards Lifesciences Corporation $EW - MarketBeat
Ninety One North America Inc. Acquires 71,017 Shares of Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences Corporation (NYSE:EW) Short Interest Down 19.2% in December - MarketBeat
VIRGINIA RETIREMENT SYSTEMS ET Al Purchases 56,000 Shares of Edwards Lifesciences Corporation $EW - MarketBeat
Cwm LLC Purchases 43,065 Shares of Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences (NYSE:EW) Shares Unloaded Rep. Josh Gottheimer - MarketBeat
Mirova US LLC Has $219.47 Million Position in Edwards Lifesciences Corporation $EW - MarketBeat
Farmers & Merchants Investments Inc. Sells 15,037 Shares of Edwards Lifesciences Corporation $EW - MarketBeat
Stifel Upgrades Edwards Lifesciences (EW) - MSN
Edwards Lifesciences Corp Stock Price Live, Charts & News - The Economic Times
Edwards Sapien M3 Valve Gets FDA Approval - Orange County Business Journal
World Investment Advisors Has $2.81 Million Stake in Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences Corporation $EW Shares Sold by Litman Gregory Wealth Management LLC - MarketBeat
Edwards Lifesciences Corp (EW) Stock Price History & Data - Traders Union
Covea Finance Takes Position in Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences Corporation (NYSE:EW) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
How Do Investors Really Feel About Edwards Lifesciences Corp? - Sahm
Transcatheter Mitral Valve Replacement System Receives FDA Clearance - Diagnostic and Interventional Cardiology
HALPER SADEH LLC ENCOURAGES EDWARDS LIFESCIENCES CORPORATION SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS - Finviz
Edwards Lifesciences Corp (EW) Stock Price, Trades & News - GuruFocus
Edwards Lifesciences Corporation $EW Shares Sold by OLD National Bancorp IN - MarketBeat
FDA Approves Edwards Lifesciences' SAPIEN M3 Mitral Valve Replacement System as First Transseptal Transcatheter Therapy - BioSpace
Edwards Lifesciences (EW): Assessing Valuation After Recent Share Price Strength - Yahoo Finance
EW SEC FilingsEdwards Lifesciences Corp 10-K, 10-Q, 8-K Forms - Stock Titan
Edwards lands first FDA approval for transcatheter MVR - BioWorld MedTech
The Zacks Analyst Blog Highlights Cardinal Health, Medtronic, Intuitive Surgical and Edwards Lifesciences - Yahoo Finance
Edwards Lifesciences Says FDA Approves Valve Replacement System - MarketScreener
Edwards wins FDA approval for Sapien M3 mitral valve, marking first transseptal transcatheter therapy - MassDevice
Edwards Lifesciences’ SAPIEN M3 becomes first FDA-approved mitral valve system - Investing.com
Edwards Lifesciences gets FDA approval for SAPIEN M3 mitral valve system By Investing.com - Investing.com South Africa
Edwards Lifesciences gets FDA approval for SAPIEN M3 mitral valve system - Investing.com Canada
FDA approves Edwards Lifesciences' Sapien M3 mitral valve replacement system as first transseptal transcatheter therapy - marketscreener.com
FDA Approves Edwards Lifesciences' SAPIEN M3 Mitral Valve Replacement System as First Transseptal Transcatheter Therapy – Company AnnouncementFT.com - Financial Times
OFI Invest Asset Management Raises Stock Holdings in Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences Corporation $EW Shares Sold by Legacy Wealth Asset Management LLC - MarketBeat
Edwards Lifesciences Corp. stock outperforms competitors on strong trading day - MarketWatch
Edwards Lifesciences Advances Smart Surgery Monitoring With Completed SMART TRENDS Study - TipRanks
Seilern Investment Management Ltd Sells 183,101 Shares of Edwards Lifesciences Corporation $EW - MarketBeat
How JP Morgan’s Upgrade and 2026 Conference Spotlight Will Impact Edwards Lifesciences (EW) Investors - simplywall.st
Edwards Lifesciences (BSP:E1WL34) EV-to-OCF : 46.58 (As of Dec. 20, 2025) - GuruFocus
Edwards Lifesciences Corporation $EW Shares Sold by Texas Permanent School Fund Corp - MarketBeat
Profit Review: How Edwards Lifesciences Corporation stock compares to industry benchmarksPrice Action & Capital Efficiency Focused Ideas - Улправда
Finanzdaten der Edwards Lifesciences Corp-Aktie (EW)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.80%
2.38%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):